Skip to main content
SpringerLink
Log in

The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background

Uterine carcinosarcomas are rare and highly aggressive tumours. Although surgery is the cornerstone of treatment, the extent of the procedure remains controversial. We sought to evaluate the available literature data regarding the rationale of lymphadenectomy and its possible impact on survival.

Methods

A systematic Medline, PubMed and Scopus search with special focus on the publications of the last decade.

Results

Carcinosarcomas have similar clinical characteristics and behaviour with grade 3 endometrioid or aggressive variants of uterine adenocarcinoma. All studies have demonstrated that the FIGO stage of disease is the most important prognostic factor, followed by the depth of myometrial invasion, extra-uterine spread and positive peritoneal cytology. Moreover, lymph node involvement will be found in 14–38% of patients undergoing lymphadenectomy. This figure is similar to the one reported for endometrial carcinoma. Therefore, lymphadenectomy is mandatory for staging purposes. Regarding its impact on survival, the majority of studies confirm a significant survival benefit. The possible mechanisms for the improvement of survival from lymphadenectomy include removal of micro-metastatic foci, reduction of recurrence risk (removal of “target tissue”) and mechanical circumvallate of the disease. Given that 5–38% of the patients will experience local recurrence and 30–83% distant metastases, lymphadenectomy reduces the risk of the first and identifies patients in advanced stage that may benefit from adjuvant chemotherapy, aiming to reduce the second and ultimately improve overall survival.

Conclusions

Our review data fully justifies the rationale of lymphadenectomy, which beyond staging information seems to offer a measurable survival benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88(12):2782–2786

    Article  CAS  PubMed  Google Scholar 

  2. Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, Gates EJ, Di Maio T, Marzec T (1997) Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 65(1):158–163

    Article  CAS  PubMed  Google Scholar 

  3. Nordal RR, Thoresen SO (1997) Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. Eur J Cancer 33(6):907–911

    Article  CAS  PubMed  Google Scholar 

  4. Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson EM, Yandell RB (1989) Mixed müllerian tumors of the uterus: a clinicopathologic study. Obstet Gynecol 74(3 Pt 1):388–392

    CAS  PubMed  Google Scholar 

  5. Kahanpää KV, Wahlström T, Gröhn P, Heinonen E, Nieminen U, Widholm O (1986) Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 67(3):417–424

    PubMed  Google Scholar 

  6. Schweizer W, Demopoulos R, Beller U, Dubin N (1990) Prognostic factors for malignant mixed müllerian tumors of the uterus. Int J Gynecol Pathol 9(2):129–136

    Article  CAS  PubMed  Google Scholar 

  7. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ (2004) Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 58(3):786–796

    PubMed  Google Scholar 

  8. Galaal K, Kew FM, Tam KF, Lopes A, Meirovitz M, Naik R, Godfrey KA, Hatem MH, Edmondson RJ (2009) Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol 143(2):88–92 Epub 2009 Feb 7

    Article  CAS  PubMed  Google Scholar 

  9. Nemani D, Mitra N, Guo M, Lin L (2008) Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 111(1):82–88

    Article  PubMed  Google Scholar 

  10. Morice P, Rodrigues A, Pautier P, Rey A, Camatte S, Atallah D, Pomel C, Lhommé C, Haie-Meder C, Duvillard P, Castaigne D (2003) Surgery for uterine sarcoma: review of the literature and recommendations for the standard surgical procedure. Gynecol Obstet Fertil 31(2):147–150

    Article  CAS  PubMed  Google Scholar 

  11. Wright JD, Seshan VE, Shah M, Schiff PB, Burke WM, Cohen CJ, Herzog TJ (2008) The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 199(5):536.e1–536.e8 (Epub 3 June 2008)

    Article  Google Scholar 

  12. Park JY, Kim DY, Kim JH, kim YT, Nam JH (2010) The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early stage carcinosarcoma of uterus. Ann Surg Oncol 17(3):861–868

    Article  PubMed  Google Scholar 

  13. Winter R, Ostor A, Kapp K, Petru E (2004) Primary treatment of uterine sarcomas. In: Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas G (eds) Gynecologic cancer. Controversies in management. Elsevier, New York, pp 301–316

    Chapter  Google Scholar 

  14. Sutton G, Kavanagh J, Wolfson A, Tornos C (2005) Corpus: mesenchymal tumors. In: Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME (eds) Principles and practice of gynecologic oncology, 4th edn. Lippincott, Philadelphia, pp 873–894

    Google Scholar 

  15. Hacker NF (2005) Uterine cancer. In: Berek JS, Hacker NF (eds) Practical gynecologic oncology, 4th edn. Lippincott, Philadelphia, pp 397–442

    Google Scholar 

  16. Hacker NF, Marsden DE (2006) Surgery for uterine cancer. In: Luesley DM, Lawton FG, Berchuck A (eds) Uterine cancer. Taylor & Francis, London, pp 142–144

    Google Scholar 

  17. Kitchener HC, Trimble EL (2009) Endometrial cancer state of the art meeting. Int J Gynecol Cancer 19(1):134–140

    PubMed  Google Scholar 

  18. Iwasa Y, Haga H, Konishi I, Kobashi Y, Higuchi K, Katsuyama E, Minamiguchi S, Yamabe H (1998) Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer 82(3):512–519

    Article  CAS  PubMed  Google Scholar 

  19. McCluggage WG (2002) Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 12(6):687–690

    Article  CAS  PubMed  Google Scholar 

  20. McCluggage WG (2002) Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 40(4):309–326

    Article  CAS  PubMed  Google Scholar 

  21. Brown L (2008) Pathology of uterine malignancies. Clin Oncol (R Coll Radiol) 20(6):433–447 Epub 2008 May 21

    CAS  Google Scholar 

  22. Kernochan LE, Garcia RL (2009) Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 7(5):550–556

    CAS  PubMed  Google Scholar 

  23. Nola M, Babić D, Ilić J, Marusić M, Uzarević B, Petrovecki M, Sabioncello A, Kovac D, Jukić S (1996) Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 78(12):2543–2550

    Article  CAS  PubMed  Google Scholar 

  24. Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, Van Robaeys J, Neven P, Moerman P, Vergote I (2005) Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 98(2):274–280

    Article  PubMed  Google Scholar 

  25. Rovirosa A, Ascaso C, Ordi J, Abellana R, Arenas M, Lejarcegui JA, Pahisa J, Puig-Tintoré LM, Mellado B, Armenteros B, Iglesias X, Biete A (2002) Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys 52(5):1320–1329

    Article  PubMed  Google Scholar 

  26. Benito V, Lubrano A, Arencibia O, Andújar M, Alvarez E, Medina N, Falcón JM, Falcón O (2009) Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands. Int J Gynaecol Obstet (Epub ahead of print)

  27. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH (2008) Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007. J Cancer Res Clin Oncol 134(12):1277–1287 Epub 2008 May 28

    Article  PubMed  Google Scholar 

  28. Kokawa K, Nishiyama K, Ikeuchi M, Ihara Y, Akamatsu N, Enomoto T, Ishiko O, Motoyama S, Fujii S, Umesaki N (2006) Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990–2003). Int J Gynecol Cancer 16(3):1358–1363

    Article  CAS  PubMed  Google Scholar 

  29. Wu TI, Hsu KH, Huang HJ, Hsueh S, Chou HH, Tsai CS, Ho KC, Chao A, Chang TC, Lai CH (2008) Prognostic factors and adjuvant therapy in uterine carcinosarcoma. Eur J Gynaecol Oncol 29(5):483–488

    CAS  PubMed  Google Scholar 

  30. Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG (1997) An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol 67(3):316–321

    Article  CAS  PubMed  Google Scholar 

  31. Yalman D, Ozsaran Z, Baltalarli B, Demir O, Ozdemir N, Aras A (2008) Results of postoperative radiotherapy in the treatment of uterine sarcomas: a retrospective analysis of 46 patients. Eur J Gynaecol Oncol 29(1):46–51

    CAS  PubMed  Google Scholar 

  32. El Husseiny G, Al Bareedy N, Mourad WA, Mohamed G, Shoukri M, Subhi J, Ezzat A (2002) Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol 25(3):256–260

    Article  CAS  PubMed  Google Scholar 

  33. Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C (2002) Analysis of clinicopathologic factors in malignant mixed Müllerian tumors of the uterine corpus. Int J Gynecol Cancer 12(4):348–353

    Article  CAS  PubMed  Google Scholar 

  34. Ozguroglu M, Bilici A, Ilvan S, Turna H, Atalay B, Mandel N, Sahinler I (2008) Determining predominating histologic component in malignant mixed Müllerian tumors: is it worth it? Int J Gynecol Cancer 18(4):809–812 Epub 2007 Sep 24

    Article  CAS  PubMed  Google Scholar 

  35. Leath CA 3rd, Numnum TM, Kendrick JE 4th, Frederick PJ, Rocconi RP, Conner MG, Straughn JM Jr (2009) Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer 19(5):888–891

    Google Scholar 

  36. Gadducci A, Cosio S, Romanini A, Genazzani AR (2008) The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65(2):129–142 Epub 2007 Aug 13. Review

    Article  PubMed  Google Scholar 

  37. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71(4 Suppl):1702–1709

    CAS  PubMed  Google Scholar 

  38. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S105–S143

    Article  PubMed  Google Scholar 

  39. Ayhan A, Tuncer ZS, Tanir M, Yüce K, Ayhan A (1997) Uterine sarcoma: the Hacettepe hospital experience of 88 consecutive patients. Eur J Gynaecol Oncol 18(2):146–148

    CAS  PubMed  Google Scholar 

  40. Temkin SM, Hellmann M, Lee YC, Abulafia O (2007) Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer 17(1):215–219

    Article  CAS  PubMed  Google Scholar 

  41. Akahira J, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, Tase T, Wada Y, Ito K, Niikura H, Yamada H, Sato A, Sasano H, Yaegashi N (2006) Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology 71(5–6):333–340 Epub 2007 Aug 9

    Article  PubMed  Google Scholar 

  42. Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, Yamashiro K, Kanemoto T, Kudo R (2004) Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 67(1):33–39

    Article  PubMed  Google Scholar 

  43. Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF (2001) Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. Cancer 91(8):1437–1443

    Article  CAS  PubMed  Google Scholar 

  44. Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB (2008) European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44(6):808–18 (Epub 2008 Apr 2). Erratum in: Eur J Cancer. 2008 Jul; 44(11):1612

    Google Scholar 

  45. Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW (1998) The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 68(1):8–13

    Article  CAS  PubMed  Google Scholar 

  46. Shimizu S, Yajima M, Yoshii A, Nishikawa T, Ohta H (2009) Malignant pericardial effusion and cardiac tamponade originating from uterine carcinosarcoma. Arch Gynecol Obstet 279(3):373–375 Epub 2008 Jun 12

    Article  PubMed  Google Scholar 

  47. Yoney A, Eren B, Eskici S, Salman A, Unsal M (2008) Retrospective analysis of 105 cases with uterine sarcoma. Bull Cancer 95(3):E10–17

    Google Scholar 

Download references

Conflict of interest

The authors declare that no conflict of interest exists.

Author information

Authors and Affiliations

  1. Department of Gynaecology, Metaxa Memorial Cancer Hospital, Botassi 51, 18537, Piraeus, Greece

    G. Vorgias

  2. Department of Obstetrics and Gynaecology, University of Athens School of Medicine, Aretaieion Hospital, Athens, Greece

    S. Fotiou

Authors
  1. G. Vorgias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Fotiou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Vorgias.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vorgias, G., Fotiou, S. The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet 282, 659–664 (2010). https://doi.org/10.1007/s00404-010-1649-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-010-1649-0

Keywords

Search

Navigation